文献速递前列腺癌

基于血液和尿液的生物标志物用于检测临床显著性前列腺癌的评估

Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-06-10

本文综述了当前可用的基于血液和尿液的生物标志物(PHI、4Kscore、MPS、SelectMDx、EPI、IsoPSA)用于检测GG≥2前列腺癌的文献。2015-2023年的验证数据显示,这些标志物在90-95%敏感性下提供约15-50%特异性,可避免多达15-50%的不必要前列腺穿刺,同时保持对90-95%的GG≥2癌症的检测。文献进一步支持PSA后生物标志物检测的作用,但标志物与mpMRI联合或序贯应用的最佳方案仍存疑问。

要点

  • 当前血液/尿液生物标志物在90-95%敏感性下特异性约15-50%,用于检测GG≥2前列腺癌。
  • PSA升高男性中二次使用生物标志物可避免多达15-50%的不必要穿刺,同时保持90-95%的GG≥2癌症检测。
  • 生物标志物与mpMRI联合或序贯应用的最佳方案仍存疑问。

核心结论

  • 当代文献进一步支持PSA后生物标志物检测的拟定作用,即减少侵入性穿刺的使用,同时保持对GG≥2癌症的高敏感性检测。
  • 关于生物标志物与mpMRI联合或序贯应用的最佳方案仍存疑问。

研究设计与样本

  • 本文为文献综述,回顾了描述当前可用的基于血液和尿液的生物标志物用于检测GG≥2癌症的文献,包括PHI、4Kscore、MPS、SelectMDx、EPI和IsoPSA。
  • 重点关注生物标志物作为PSA后、穿刺前的二次检测,如临床指南所提出的。

主要发现

  • 2015-2023年的当代验证数据显示,当前可用的生物标志物在90-95%敏感性下对GG≥2前列腺癌提供约15-50%特异性。
  • 临床上,PSA升高男性中二次使用生物标志物检测可避免多达15-50%的不必要前列腺穿刺,同时保持对传统「全部穿刺」方法下可检测的90-95%的GG≥2癌症的检测。

关键数值与推荐

  • 结局指标包括测试性能指标——敏感性、特异性、阴性预测值(NPV)和阳性预测值(PPV)——以及使用生物标志物带来的临床结局(即避免的不必要穿刺、遗漏的GG≥2癌症)。

局限性

  • 关于生物标志物与mpMRI联合或序贯应用的最佳方案仍存疑问。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recognizing the limitations of prostate-specific antigen (PSA) screening and the morbidity of prostate biopsies, several blood- and urine-based biomarkers have been proposed for pre-biopsy risk stratification. These assays aim to reduce the frequency of unnecessary biopsies (i.e., negative or Grade Group 1 [GG1]) while maintaining highly sensitive detection of clinically significant cancer (GG ≥ 2) prostate cancer. METHODS: We reviewed the literature describing the use of currently available blood- and urine-based biomarkers for detection of GG ≥ 2 cancer, including the Prostate Health Index (PHI), 4Kscore, MyProstateScore (MPS), SelectMDx, ExoDx Prostate Intelliscore (EPI), and IsoPSA. To facilitate clinical application, we focused on the use of biomarkers as a post-PSA secondary test prior to biopsy, as proposed in clinical guidelines. Our outcomes included test performance measures-sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV)-as well as clinical outcomes resulting from biomarker use (i.e., unnecessary biopsies avoided, GG ≥ 2 cancers missed). RESULTS: Contemporary validation data (2015-2023) reveal that currently available biomarkers provide ~15-50% specificity at a sensitivity of 90-95% for GG ≥ 2 PCa. Clinically, this indicates that secondary use of biomarker testing in men with elevated PSA could allow for avoidance of up to 15-50% of unnecessary prostate biopsies, while preserving detection of 90-95% of GG ≥ 2 cancers that would be detected under the traditional "biopsy all" approach. CONCLUSIONS: The contemporary literature further supports the proposed role of post-PSA biomarker testing to reduce the use of invasive biopsy while maintaining highly sensitive detection of GG ≥ 2 cancer. Questions remain regarding the optimal application of biomarkers in combination or in sequence with mpMRI.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Robinson HS, Lee SS, Barocas DA, et al. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38858447. doi:10.1038/s41391-024-00840-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。